Andera et al. back Dynacure in €47m round

Andera Partners led the financing round, joined by Pontifax, Idinvest Partners and historical backers Kurma Partners and BPI France, which first invested in the business in 2016 and 2017 respectively.

The new round of funding will help the biotechnology company to advance its lead programme into clinical development. 

Company
Dynacure is a biotechnology company developing new treatments for patients affected by specific serious orphan diseases – diseases that affect only a few people nationwide. In its first drug discovery programme, Dynacure is focusing on centronuclear myopathies (CNM), a rare, debilitating disease affecting children and young adults.

Founded in 2016, Dynacure is a spin-out from the institute of genetic, molecular and cellular biology in Strasbourg. The business is based in Illkirch-Graffenstaden.

People
Dynacure – Stephane van Rooijen (CEO).
Andera Partners – Raphael Wisniewski (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• Andera Partners
• IDInvest Partners (AGF Private Equity)